Figure 2.
SETD2 facilitates imatinib sensitivity in CML cell lines. A, B, Protein expression levels of SETD2, H3K36me3 and related histone‐modified sites (A) and mRNA expression level of SETD2 (B) in TF1‐BA cells transfected with different SETD2‐targeted shRNA. C, IC50 curves of imatinib (IM)‐treated SETD2‐KD‐BA cells. D, E, Flow cytometric assay of the apoptotic percentage of IM‐treated SETD2‐KD‐BA cells. F, G, Protein expression levels of SETD2, H3K36me3 and relevant histone‐modified sites (F) and mRNA expression level of SETD2 (G) in SETD2‐OE‐BAR cells. H, IC50 curves of IM‐treated SETD2‐OE‐BAR cells. I, J, Flow cytometric assay of the apoptotic percentage of IM‐treated SETD2‐OE‐BAR cells. Data are presented as the mean ± SD of at least three independent experiments. ***P < 0.001, by ANOVA